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Ventricular tachyarrhythmia episodes, both primary ven-
tricular ﬁbrillation (VF) and fast ventricular tachycardia (VT)
degenerating to VF, are still important causes of sudden
cardiac death (SCD) that can potentially be prevented by an
implanted cardioverter-deﬁbrillator (ICD) (1). Two clinical
trials (2,3), both published about 10 years ago, showed that
patients with an impaired left ventricular systolic function
had a survival beneﬁt if prophylactically implanted with
an ICD. On the basis of these two trials, implantation of an
ICD device for so-called primary prevention has become
an integral part of international guidelines and is widely usedSee page 2261in clinical practice. This treatment strategy has been chal-
lenged because of many questionable features of prophylactic
ICD therapy (4). ICD candidates today have lower rates of
malignant arrhythmias and have better outcomes without an
ICD than the patients included in the seminal trials 10 years
ago as the result of improvements in pharmacological and
other non-ICD therapy, especially because of improved heart
failure treatment and early revascularization in coronary ar-
tery disease and myocardial infarction. Second, less than one
third of patients with a prophylactically implanted ICD
device ever receive an appropriate shock from their device,
and the risk of death from non-arrhythmic causes may
presently outweigh the risk of death from ventricular
tachyarrhythmia in these patients. Furthermore, every
appropriate ICD shock does not prevent SCD, because
presumably <50% of appropriate shocks are truly life-saving
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term complications and side effects of ICD treatment may
have been underestimated in certain patient groups (7).
Two patient groups can be identiﬁed that never receive any
beneﬁt from their implanted ICD despite the impaired left
ventricular ejection fraction. One group is at a very low risk of
havingVForVTevents, so that even over a long period of time,
no life-saving therapy is triggered or needed. The other group
comprises comorbid and/or elderly patients with a high mor-
tality risk independent of the ICD.There is an expert consensus
that more accurate strategies for the selection of patients for
ICD therapy are needed to increase the effectiveness of this
therapy (8). Therefore, clinicians and scientists have sought
other methods that could identify more accurately the electro-
physiological substrate and/or presence of arrhythmia triggers
of VF and VT events than the measurement of left ventricular
ejection fraction and thereby identify patients who are most
suitable for prophylactic ICD therapy (8).
In this issue of the Journal, Gao et al. (9) report that
circulating levels of SCN5A gene variants are strong pre-
dictors of appropriate ICD therapies. In the ﬁrst part of the
study, the investigators show that circulating expression levels
of the variants have a close correlation with myocardial tissue
levels, which suggests that simple measurements of these
biomarkers from the blood sample could be used as surrogates
of myocardial expression of these gene variants. Alternative
mRNA splicing is a mechanism that can change the gene
expression by creating a variety of gene products from a single
DNA message. The same authors have earlier reported that
some signals common to heart failure increase twomyocardial
splicing factors that decrease the full-length SCN5A tran-
script and protein and decrease Naþ current (10). In a mouse
model, a signiﬁcant reduction in myocardial conduction and
an increase in arrhythmic risk were also reported (11). In this
report, the authors extend these observations to humans and
show that the measurements of these splicing variants from
the blood samples could be used in the clinical setting as
predictors of appropriate ICD shocks.
Despite these interesting preliminary results, several
important questions remain unanswered. It is possible that
these excellent results in terms of the high predictive power of
these biomarkers cannot be replicated in other larger patient
samples. It is difﬁcult to understand that some risk markers
reﬂecting a single electrophysiological abnormality, such as
impaired myocardial signal conduction, can predict VF and/
or fast VT with such a high accuracy as in this study because
the mechanistic backgrounds of these events are heteroge-
neous. For example, the mechanisms of ventricular tachyar-
rhythmia events are different in ischemic and non-ischemic
cardiomyopathy, and VF and VT can be triggered by a variety
of factors, such as an acute ischemic event, electrolyte
imbalance, acute cardiac decompensation, autonomic imbal-
ance, and so forth (1). Thus, it may not be realistic to assume
that an altered expression of a speciﬁc gene variant could
explain all these mechanisms. A combination of two or more
risk variables will ideally be needed to improve the risk
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2271stratiﬁcation and selection of patients for prophylactic ICD
therapy (8). Several other unanswered questions remain, such
as the incremental value of this biomarker as compared with
many other established risk variables, cost-effectiveness of the
measurement of these variants, and their clinical utility in
larger samples to change the recommended therapy.
Despite the obvious limitations of this preliminary study,
this is an important step to better understand the mecha-
nisms of fatal cardiac arrhythmias and to better risk-stratify
the patients to these events. It will be interesting to see
further studies in this era of research. Because the random-
ized prophylactic ICD trials are too expensive and ethically
unacceptable in patients with current indications for pro-
phylactic ICD therapy, the role of these novel biomarkers
compared with several other risk variables should ideally be
tested in large, non-randomized, prospective trials, such as
the ongoing multicenter EU-CERT study, assessing several
variables obtained from the standard 12-lead and 24-h
electrocardiogram as well as biomarkers as predictors of the
beneﬁt from ICD therapy in a large sample of patients.
Before these analyses are conducted in large patient samples,
the role of the circulating gene variants in predicting VF and
VT events should be conﬁrmed in other independent sam-
ples of patients with ICDs.
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